CClinicalTrials.gg
Active, not recruitingNCT03279276Updated Apr 8, 2022

Selecting the Right Hip Prosthesis for Young Patients

An interventional study of Total Hip Arthroplasty in Osteoarthritis, Hip, sponsored by Northern Orthopaedic Division, Denmark. Active, not recruiting at 1 site in Denmark. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2022-04-08.

Sponsored by Northern Orthopaedic Division, Denmark · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

There have been no previously published clinical randomized studies comparing Primoris®, short stem, hip prosthesis with standard uncemented hip arthroplasty in relation to bone density and function development. This is the subject for this study.

Read the detailed description

The overall purpose of this study is to show whether the Primoris® hip prosthesis results in a smaller loss of bone density than standard hip prosthesis, which in the longer term may result in an improved survival of prosthesis No. 2 after revision / replacement of a Primoris® hip prosthesis.

The primary outcome is periprosthetic bone quality in Primoris® hip prosthesis compared to standard hip prosthesis measured by DXA scanning.

The secondary outcomes are to assess:

  1. The hip function measured by gait analysis.
  2. Hip strength at pressure gauge.
  3. Prosthetic migration / migration measured by radio-stereometric analysis (RSA).
  4. Patient satisfaction measured by PROMs.
02

Conditions studied

  • Osteoarthritis, Hip

Browse trials for

Keywords

  • Hip arthroplasty
03

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Women ≤ 45 years or men ≤ 55 years with hip osteoarthritis, suitable for hip prosthesis.

Patients who wish to participate in the project and give written consent after oral and written information.

Exclusion criteria

Exclusion Criteria:

  1. Patients with previous bone disease, metabolic disease, including diabetes, or the use of drugs that affect bone density.
  2. Smoking more than 20 cigarettes daily
  3. Patients with fracture in the femur or acetabulum.
  4. Patients who do not understand the given patient information
  5. Competing disorder requiring treatment with antiinflammatory drugs (NSAIDs, steroid, cytostatics).
  6. Estimated residual life \<10 years
  7. Rheumatoid arthritis or other arthritis (eg psoriasis arthritis).
  8. Previous surgery on the relevant hip joint.
  9. Co-Morbidity (ASA Group 3-5).
  10. Neurological disorder that compromises motor skills and rehabilitation.
  11. Pregnancy.
  12. Osteoarthritis secondary to mb. Calvé-Legg-Perthes / Avascular Caput Necrosis, Epiphysiolysis Capitis Femoris and Multiple Epiphysic Dysplasia.
  13. Acetabular dysplasia with secondary subluxation (Crowe grade II to IV).
  14. Previously detected osteoporosis or osteoporosis detected by current DXA scanning.
  15. Ongoing treatment with osteoporosis medicine (bisphosphonates, estrogen receptor modulators and parathyroid hormone, etc.).
  16. Aseptic caput necrosis (posttraumatic, idiopathic).
  17. Varus or valgus deformity in proximal femur (collum angle \<125 ° or> 145 °.)
  18. Collum femoris assessed too retro- or anteverted.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Primoris

    Total hip arthroplasty surgery using a Primoris® femur component, Exceed ® acetabular cup + E-poly liner ®.

    Procedure: Total Hip Arthroplasty

  • Active comparator
    Echo

    Total hip arthroplasty surgery using a standard uncemented Echo® femur component, Exceed ® acetabular cup + E-poly liner ®.

    Procedure: Total Hip Arthroplasty

Interventions

  • ProcedureTotal Hip Arthroplasty

    The usual procedures of the department: Moore incision and insertion of uncemented joints (exceed with vitamin E enriched polyethylene liner and 32 or 36 mm head). Cyclokaprone is administered peroperatively (bleeding-reducing), antibiotics and thrombosis prophylaxis. Follow the usual rehabilitation regimes, fast track, incl. Use of crutches and must support within the pain limit, possibly with crutches the first 4 weeks after surgery, then full load. By default, postoperative X-ray and RSA recordings will be performed on the 1st or 2nd postoperative day. The surgery will be performed by specialist physicians in orthopedic surgery associated with the hip arthroplasty sector.

05

What researchers measure

Primary outcomes

  1. Bone Mineral Density

    Bone density around the prosthesis measured by serial Dual X-ray Absorptiometry (DXA) scans.

    Time frame: 2 -10 years

Secondary outcomes

  1. Gait analysis

    Walking function measured by gait analysis and hip strength at dynamometer test pre and 12 months postoperatively.

    Time frame: 1 year

  2. Radio Stereometric Analysis (RSA)

    Prosthetic migration / migration measured by X-ray Radio-stereophotogrametic-analyzes

    Time frame: 2-10 years

  3. European Quality of life in 5 Dimensions (EQ5D)

    This is a well defined Patient Reported Outcome Measure (PROM) that doesn't need further explanation.

    Time frame: 2-10 years

  4. Harris Hip Score (HHS)

    This is a well defined Patient Reported Outcome Measure (PROM) that doesn't need further explanation.

    Time frame: 2-10 years

  5. Oxford Hip Score (OHS),

    This is a well defined Patient Reported Outcome Measure (PROM) that doesn't need further explanation.

    Time frame: 2-10 years

  6. University of California Los Angeles Activity Score (UCLA)

    This is a well defined Patient Reported Outcome Measure (PROM) that doesn't need further explanation.

    Time frame: 2-10 years

  7. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

    This is a well defined Patient Reported Outcome Measure (PROM) that doesn't need further explanation.

    Time frame: 2-10 years

  8. Forgotten Joint Score (FJS)

    This is a well defined Patient Reported Outcome Measure (PROM) that doesn't need further explanation.

    Time frame: 2-10 years

06

Study locations

1 site
  • Northern Orthopaedic Division, Clinic Farsø, Aalborg University Hospital
    Farsø, Northern Jutland, Denmark
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03279276
Lead sponsor
Northern Orthopaedic Division, Denmark
Responsible party
Sponsor
First posted
Sep 12, 2017
Start date
Jun 1, 2018
Primary completion
Dec 10, 2019
Completion
Dec 2029 (estimated)
Last update
Apr 8, 2022

Study contacts

Mogens Laursen, MD, PhD
principal investigator · Northern ODD

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion